Teva Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Tops Q4 EPS by 5c, Revenues Beat; Offers FY21 EPS/Revenue Guidance
February 10, 2021 7:03 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $0.68, $0.05 better than the analyst estimate of $0.63. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.37 billion.
GUIDANCE:
Teva Pharma sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.63. Teva Pharma sees FY2021 revenue of $16.4-16.8 billion, versus the consensus of $16.76 billion.
2021 business outlook:
Revenues are expected to be $16.4 - $16.8 billion (2020 actual results... More